Search

Your search keyword '"Hervella-Garces M"' showing total 14 results
Start Over Author "Hervella-Garces M"
14 results on '"Hervella-Garces M"'

1. [Translated article] Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)

Author

Navarro-Triviño, F.J., Borrego, L., Silvestre-Salvador, J.F., Mercader-García, P., Giménez-Arnau, A.M., Ortiz-de Frutos, F.J., Sanz-Sánchez, T., Melé-Ninot, G., Sánchez-Gilo, A., Zaragoza-Ninet, V., Serra-Baldrich, E., Miquel-Miquel, J., Córdoba-Guijarro, S., Rodríguez-Serna, M., Ruíz-González, I., Carrascosa-Carrillo, J.M., Gómez-de la Fuente, E., Pastor-Nieto, M.A., Heras-Mendaza, F., González-Pérez, R., Sánchez-Pedreño Guillén, P., Sánchez-Pérez, J., Gatica-Ortega, M.E., Fernández-Redondo, V., Hervella-Garcés, M., Manrique-Martínez, P., Guimaraens-Juanena, D., García-Gavín, J., Giménez-Arnau, E., Figueras-Nart, I., Curto-Barredo, L., and Armario-Hita, J.C.

Published
2024
Full Text
View/download PDF

2. Actualización de la batería estándar y batería ampliada de pruebas alérgicas de contacto por el Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC)

Author

Navarro-Triviño, F.J., Borrego, L., Silvestre-Salvador, J.F., Mercader-García, P., Giménez-Arnau, A.M., Ortiz-de Frutos, F.J., Sanz-Sánchez, T., Melé-Ninot, G., Sánchez-Gilo, A., Zaragoza-Ninet, V., Serra-Baldrich, E., Miquel-Miquel, J., Córdoba-Guijarro, S., Rodríguez-Serna, M., Ruíz-González, I., Carrascosa-Carrillo, J.M., Gómez-de la Fuente, E., Pastor-Nieto, M.A., Heras-Mendaza, F., González-Pérez, R., Sánchez-Pedreño Guillén, P., Sánchez-Pérez, J., Gatica-Ortega, M.E., Fernández-Redondo, V., Hervella-Garcés, M., Manrique-Martínez, P., Guimaraens-Juanena, D., García-Gavín, J., Giménez-Arnau, E., Figueras-Nart, I., Curto-Barredo, L., and Armario-Hita, J.C.

Published
2024
Full Text
View/download PDF

3. Alérgenos candidatos para ser incluidos en la serie estándar española a partir de los datos del Registro Español de Dermatitis de Contacto

Author

Hernández-Fernández, C.P., Mercader-García, P., Silvestre Salvador, J.F., Sánchez Pérez, J., Fernández Redondo, V., Miquel Miquel, F.J., Ortiz de Frutos, F.J., Gatica Ortega, M.E., Mora Fernández, V., Giménez Arnau, A.M., Zaragoza Ninet, V., González Pérez, R., Sanz Sánchez, T., Pastor Nieto, M.A., Serra Baldrich, E., Córdoba Guijarro, S., Heras Mendaza, F., Ruiz González, I., Rodríguez Serna, M., Hervella Garcés, M., Gallego Descalzo, M.Á., García Doval, I., and Borrego Hernando, L.

Published
2021
Full Text
View/download PDF

7. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study

Author

Mercader-Garcia, P, Pastor-Nieto, MA, Gonzalez-Perez, R, Cordoba-Guijarro, S, Gimenez-Arnau, AM, Ruiz-Gonzalez, I, Mora-Fernandez, V, Miquel, J, Silvestre-Salvador, JF, Ortiz-Frutos, FJ, Sanz-Sanchez, T, Rodriguez-Serna, M, Perez-Feal, P, Sanchez-Perez, J, Heras-Mendaza, F, Serra-Baldrich, E, Zaragoza-Ninet, V, Hervella-Garces, M, Gatica-Ortega, ME, Garcia-Doval, I, Descalzo, MA, and Borrego, L

Subjects
patch tests, cross-sectional study, methyldibromo glutaronitrile, clinical relevance, allergic contact dermatitis
Abstract

Background Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of this century. In 2008, this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN has progressively decreased. Despite that gradual decline, MDBGN is still patch-tested in most baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients, and the relevance of positive patch tests in a nationwide Spanish registry (REIDAC). Patients and methods We evaluated consecutively patch-tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests. Results One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case. Conclusion Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable.

Published
2021

8. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC 1 national cross-sectional study

Author

Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Cordoba-Guijarro S, Jimenez-Arnau AM, Ruiz-Gonzalez I, Mora-Fernández V, Miquel J, Silvestre-Salvador JF, Ortiz-Frutos FJ, Sanz-Sanchez T, Rodriguez-Serna M, Perez-Feal P, Sánchez-Pérez J, Heras-Mendaza F, Serra-Baldrich E, Zaragoza-Ninet V, Hervella-Garces M, Gatica-Ortega ME, García-Doval I, Descalzo MÁ, and Borrego L

Subjects
Allergic contact dermatitis, clinical relevance, cross-sectional study, methyldibromo glutaronitrile, patch tests
Abstract

Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of the 2000's. In 2008 this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN progressively decreased. Despite that gradual decline, it is still patch-tested in most baseline series. This study assesses the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients as well as the relevance of positive patch tests in a nationwide Spanish registry (REIDAC).

Published
2021

13. Arguments in favour of excluding MDBGN from the European baseline series. In response to "Comment on MDBGN/DBDCB, the European baseline series, and EU legislation".

Author

Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Gimenez-Arnau AM, Ruiz-Gonzalez I, Mora-Fernández V, Miquel J, Silvestre-Salvador JF, Sanz-Sanchez T, Perez-Feal P, Sánchez-Pérez J, Heras-Mendaza F, Serra-Baldrich E, Hervella-Garces M, Gatica-Ortega ME, García-Doval I, and Borrego L

Subjects
Humans, Nitriles, Patch Tests, Preservatives, Pharmaceutical, Dermatitis, Allergic Contact etiology
Published
2021
Full Text
View/download PDF

14. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study.

Author

Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Cordoba-Guijarro S, Gimenez-Arnau AM, Ruiz-Gonzalez I, Mora-Fernández V, Miquel J, Silvestre-Salvador JF, Ortiz-Frutos FJ, Sanz-Sanchez T, Rodriguez-Serna M, Perez-Feal P, Sánchez-Pérez J, Heras-Mendaza F, Serra-Baldrich E, Zaragoza-Ninet V, Hervella-Garces M, Gatica-Ortega ME, García-Doval I, Descalzo MÁ, and Borrego L

Subjects
Adult, Allergens, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Patch Tests statistics & numerical data, Cosmetics adverse effects, Dermatitis, Allergic Contact epidemiology, Nitriles adverse effects, Preservatives, Pharmaceutical adverse effects
Abstract

Background: Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of this century. In 2008, this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN has progressively decreased. Despite that gradual decline, MDBGN is still patch-tested in most baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients, and the relevance of positive patch tests in a nationwide Spanish registry (REIDAC)., Patients and Methods: We evaluated consecutively patch-tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests., Results: One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case., Conclusion: Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results